Activation of the Cholinergic Anti-Inflammatory Pathway as a Novel Therapeutic Strategy for COVID-19

The outbreak of coronavirus disease 2019 (COVID-19) underlined the urgent need for alleviating cytokine storm. We propose here that activating the cholinergic anti-inflammatory pathway (CAP) is a potential therapeutic strategy. However, there is currently no approved drugs targeting the regulatory p...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2021-02, Vol.11, p.595342-595342
Main Authors: Qin, Zhen, Xiang, Kefa, Su, Ding-Feng, Sun, Yang, Liu, Xia
Format: Article
Language:English
Subjects:
Acupuncture
Anti-Inflammatory Agents - pharmacology
cholinergic anti-inflammatory pathway
coronavirus disease 2019
COVID-19 - therapy
Cytokine Release Syndrome - therapy
cytokine storm
Cytokines - blood
Drugs, Chinese Herbal - pharmacology
Humans
Immunology
Inflammation - therapy
Neuroimmunomodulation - immunology
Nicotine - pharmacology
SARS-CoV-2
Solanaceous Alkaloids - pharmacology
therapeutic strategy
Vagus Nerve - immunology
vagus nerve stimulation
Vagus Nerve Stimulation - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The outbreak of coronavirus disease 2019 (COVID-19) underlined the urgent need for alleviating cytokine storm. We propose here that activating the cholinergic anti-inflammatory pathway (CAP) is a potential therapeutic strategy. However, there is currently no approved drugs targeting the regulatory pathway. It is evident that nicotine, anisodamine and some herb medicine, activate the CAP and exert anti-inflammation action and . As the vagus nerve affects both inflammation and specific immune response, we propose that vagus nerve stimulation by invasive or non-invasive devices and acupuncture at ST36, PC6, or GV20, are also feasible approaches to activate the CAP and control COVID-19. It is worth to investigate the efficacy and safety of the strategy in patients with COVID-19.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2020.595342